X4 Pharmaceuticals reports successful Phase 2 trial results for mavorixafor, a treatment for chronic neutropenia.

X4 Pharmaceuticals announced positive results from a Phase 2 trial of mavorixafor, a treatment for chronic neutropenia. The study showed that the drug increased participants' white blood cell counts and reduced the need for G-CSF dosing. X4 aims to fully enroll its Phase 3 trial by mid-2025 and plans to launch XOLREMDI® for WHIM syndrome in the U.S. and submit an application for European approval by early 2025.

November 13, 2024
6 Articles

Further Reading